NOAC Monitoring, Reversal Agents, and Post-Approval Safety and Effectiveness Evaluation: A Cardiac Safety Research Consortium Think Tank

Abstract Four non-vitamin K antagonist oral anticoagulants (NOACs) (dabigatran, rivaroxaban, apixaban, and edoxaban) have been approved in the U.S. for treatment of atrial fibrillation (AF) and venous thromboembolic disease (VTE). They have been as or more effective than the prior standards of care, with less fatal or intracranial bleeding, fewer drug and dietary interactions, and greater patient convenience. Nonetheless, the absence of the ability for clinicians to assess compliance or washout with a simple laboratory test (or to adjust dosing with a similar assessment) and the absence of an antidote to rapidly stop major hemorrhage or to enhance safety in the setting of emergent or urgent surgery/procedures have been limitations to greater NOAC usage and better thromboembolic prevention. Accordingly, a Cardiac Research Safety Consortium “think tank” meeting was held in February 2015 to address these concerns. This manuscript reports on the discussions held and the conclusions reached at that meeting.